Meta-Analysis of the Reversible Inhibitors of Monoamine Oxidase Type A Moclobemide and Brofaromine for the Treatment of Depression

Lotufo-Neto, Francisco

doi:10.1016/s0893-133x(98)00075-x

Cited by 146 publications

(80 citation statements)

References 111 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As described in the Introduction, Lotufo-Neto et al (1999) reported a meta-analysis of antidepressant effects of MAO inhibitors and pointed out the possibility that non-selective MAO inhibitors are more effective than RIMA. Our results are consistent with their meta-analysis results.…”

Section: Discussionmentioning

confidence: 99%

“…Moreover, Larsen et al (1991) reported that RIMA has equal antidepressant effects to those of irreversible MAO inhibitors. However, Lotufo-Neto et al (1999) examined antidepressant effects of MAO inhibitors in a 4 meta-analysis and described the possibility that non-selective MAO inhibitors are more effective than RIMA. Consequently, it is likely that MAO-B inhibition also contributes to an antidepressant effect.…”

Section: Consequently Mao Inhibitors Have Been Used Only Infrequentlmentioning

confidence: 99%

See 1 more Smart Citation

Combined treatment with MAO-A inhibitor and MAO-B inhibitor increases extracellular noradrenaline levels more than MAO-A inhibitor alone through increases in β-phenylethylamine

Kitaichi

Inoue

Nakagawa

et al. 2010

European Journal of Pharmacology

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Consequently Mao Inhibitors Have Been Used Only Infrequentlmentioning

confidence: 99%

Combined treatment with MAO-A inhibitor and MAO-B inhibitor increases extracellular noradrenaline levels more than MAO-A inhibitor alone through increases in β-phenylethylamine

Kitaichi

Inoue

Nakagawa

et al. 2010

European Journal of Pharmacology

View full text Add to dashboard Cite

show abstract

“…Even though it was never introduced into the US, moclobemide has been used successfully in other parts of the world (Chen & Ruch, 1993). In most countries, still selective serotonin reuptake inhibitors (SSRIs) were first-line treatments, except for Finland and Australia where moclobemide is widely used as first antidepressant therapy (Lotufo-Neto, Trivedi & Thase, 1999). Moclobemide is in use in many countries and is typically prescribed in the range of 300 to 450 mg/day with optimal benefit in some patients at doses of greater or equal to 900 mg/day.…”

Section: Reversible Selective Mao-a Inhibitors (Rima)mentioning

confidence: 99%

Monoamine Oxidase Inhibitors—Revisiting a Therapeutic Principle

Entzeroth¹,

Ratty²

2017

OJD

View full text Add to dashboard Cite

Over more than 60 years, monoamine oxidase (MAO) inhibitors are available for therapy of central nervous diseases. Although they have shown to be efficacious specifically in the treatment of major depressive disorders and treatment-resistant depression, they became less a therapeutic choice for the physicians mostly due to severe side effects, such as liver failure and hypertensive crisis associated specifically with the first generation of inhibitors. Nevertheless, this class of drugs is still being used for treatment specifically as more selective and reversible inhibitors became available and will provide clinicians with additional treatment options. The current review revisits monoamine oxidase inhibitors and their potential in the treatment of human diseases, such as anxiety, depression, mood and personality disorders, and pain and introduces current ideas and developments.

show abstract

“…Moclobemide has been extensively evaluated in the treatment of a wide spectrum of depressive disorders and social phobia. Overall, moclobemide appears to be safe and devoid of major side effects, although it is considered as a mild antidepressant, better tolerated by older patients [175][176][177][178][179][180][181]. Moclobemide undergoes extensive metabolism with less than 1 % of the dose being excreted unchanged.…”

Section: Inhibition Of Maomentioning

confidence: 99%